Navigation Links
Halozyme Therapeutics Reports 2008 First Quarter Financial Results
Date:5/8/2008

in combination with PH20.

-- New safety and pharmacokinetic data from a second generation

manufacturing process for recombinant human PH20 enzyme. The data from

three studies were presented at the European Federation for

Pharmaceutical Sciences meeting for Development of Safe Protein

Therapeutics: Preclinical, Clinical and Regulatory Issues. The

presented studies investigated the IV and subcutaneous (SC) safety

assessment of PH20 administered to non-human primates at significantly

higher doses than previously examined. PH20 from a first generation

manufacturing process has been studied in a different formulation with

lower concentrations for SC injection as an adjuvant to increase

absorption and dispersion of other injected drugs and for SC fluid

administration. In a pharmacokinetic (PK) dose-range finding study,

doses up to 3,600,000 U/kg (30mg/kg) of the second generation enzyme

were well-tolerated following either IV or SC dosing.

-- Publication of the INFUSE-LR clinical trial results in the Journal of

Palliative Medicine, the official journal of the American Academy of

Palliative Medicine (Thomas JR et al. J Pall Med. December 2007;

19(6):1312-1320). The authors of this publication concluded from this

volunteer subject study that clinically relevant fluid volumes can be

rapidly delivered subcutaneously with HYLENEX in a well-tolerated

manner without the need for an infusion pump. The findings suggest

that this method of hydration could potentially replace intravenous

infusions in many clinical settings and that further studies with

HYLENEX, in patients, are warranted.

Upcoming Scientific Data Presentations

-- International Investigative Dermatology - May 14-17th - presentation

of "Temporal-Spatial Con
'/>"/>

SOURCE Halozyme Therapeutics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related biology technology :

1. Halozyme Therapeutics to Hold Pipeline Update Conference Call on May 9
2. Halozyme Therapeutics Reports Fourth Quarter and Year End 2007 Financial Results
3. Halozyme Therapeutics Presents Favorable New Safety and Pharmacokinetic Data on rHuPH20 Enzyme Produced Via New Manufacturing Process at European Federation for Pharmaceutical Sciences
4. Halozyme Therapeutics to Hold Pipeline Update Conference Call on March 14
5. Halozyme Therapeutics to Present at the BIO CEO and Investor Conference and the Roth Growth Stock Conference
6. Halozyme Therapeutics Amends Stockholder Rights Plan
7. Halozyme Therapeutics Reports 2007 Third Quarter Financial Results
8. Halozyme Therapeutics to Present at UBS 2007 Global Life Sciences Conference
9. Baxter and Halozyme Announce Collaboration for Development of Subcutaneous GAMMAGARD LIQUID(TM) Administration Using Enhanze(TM) Technology
10. Innovative and Forward-Thinking Experts to Deliver Keynote Presentations at IBCs 13th Annual Drug Discovery & Development of Innovative Therapeutics World Congress
11. ImaRx Therapeutics Signs Letter of Intent With Microbix Biosystems for the Sale of Urokinase
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/11/2014)... 2014 EPFL and the University of  ... of John P. Donoghue . The American neuroscientist ... . The new Wyss Center for ... Geneva , has named as its director ... P. Donoghue , founder of Brown University,s Institute for ...
(Date:7/10/2014)... Ouagadougou, Burkina Faso (PRWEB) July 10, 2014 ... Burkina Faso, today have access to an additional ... to increase access to contraception at all levels ... combining a lower-dose formulation of a widely used ... injection system. , Burkina Faso is the first ...
(Date:7/10/2014)... July 10, 2014 Terascala, the industry ... that Alan Swahn, a former vice president of product ... as vice president of marketing. Terascala’s software when combined ... NetApp create the highest performance and most reliable solutions ... to guide Terascala’s channel expansion and broaden its product ...
(Date:7/10/2014)... EvoDerma ’s NOOME Anti-Aging Motion has been upgraded for ... a second treatment cup to help prevent and smooth skin ... thinner on the edges for a softer contact with the ... surfaces on the face, neck and décolleté. Choose to use ... such as the cheeks and neck, or opt for the ...
Breaking Biology Technology:John P. Donoghue is Taking the Lead at the Wyss Center and is Appointed Professor at EPFL and University of Geneva 2John P. Donoghue is Taking the Lead at the Wyss Center and is Appointed Professor at EPFL and University of Geneva 3Injectable Contraceptive Launched in Burkina Faso to Expand Choice and Address Unmet Need 2Injectable Contraceptive Launched in Burkina Faso to Expand Choice and Address Unmet Need 3Injectable Contraceptive Launched in Burkina Faso to Expand Choice and Address Unmet Need 4Injectable Contraceptive Launched in Burkina Faso to Expand Choice and Address Unmet Need 5Injectable Contraceptive Launched in Burkina Faso to Expand Choice and Address Unmet Need 6Terascala Expands Executive Team 2Terascala Expands Executive Team 3Introducing a New Bonus Treatment Cup for EvoDerma’s NOOME Anti-Aging Motion 2
... /PRNewswire-Asia-FirstCall/ -- Weikang Bio-Technology Group Co., Inc. ... developer, manufacturer and marketer of Traditional Chinese Medicine (TCM), ... nutritional products in the People,s Republic of China, today ... December 31, 2010. Fiscal 2010 Financial ...
... Although top bio-pharmaceutical companies agree that Key Opinion ... a new product, increasing competition has made it difficult ... role of Medical Science Liaisons (MSLs) in forging relationships ... years. In fact, today, MSL ...
... 2011 Reportlinker.com announces that a new market ... Global Angiongenesis Inhibitors and ... This report analyzes the ... in US$ Million by the following product ...
Cached Biology Technology:Weikang Bio-Technology Announces Fiscal 2010 Financial Results 2Weikang Bio-Technology Announces Fiscal 2010 Financial Results 3Weikang Bio-Technology Announces Fiscal 2010 Financial Results 4Weikang Bio-Technology Announces Fiscal 2010 Financial Results 5Weikang Bio-Technology Announces Fiscal 2010 Financial Results 6Weikang Bio-Technology Announces Fiscal 2010 Financial Results 7Newly Updated for 2011: Medical Science Liaison Study Shows Growth in KOL Outreach, Impact 2Reportlinker Adds Global Angiongenesis Inhibitors and Stimulators Industry 2Reportlinker Adds Global Angiongenesis Inhibitors and Stimulators Industry 3Reportlinker Adds Global Angiongenesis Inhibitors and Stimulators Industry 4Reportlinker Adds Global Angiongenesis Inhibitors and Stimulators Industry 5Reportlinker Adds Global Angiongenesis Inhibitors and Stimulators Industry 6Reportlinker Adds Global Angiongenesis Inhibitors and Stimulators Industry 7Reportlinker Adds Global Angiongenesis Inhibitors and Stimulators Industry 8Reportlinker Adds Global Angiongenesis Inhibitors and Stimulators Industry 9Reportlinker Adds Global Angiongenesis Inhibitors and Stimulators Industry 10Reportlinker Adds Global Angiongenesis Inhibitors and Stimulators Industry 11Reportlinker Adds Global Angiongenesis Inhibitors and Stimulators Industry 12Reportlinker Adds Global Angiongenesis Inhibitors and Stimulators Industry 13Reportlinker Adds Global Angiongenesis Inhibitors and Stimulators Industry 14Reportlinker Adds Global Angiongenesis Inhibitors and Stimulators Industry 15Reportlinker Adds Global Angiongenesis Inhibitors and Stimulators Industry 16Reportlinker Adds Global Angiongenesis Inhibitors and Stimulators Industry 17
(Date:7/10/2014)... and other major cities in New Mexico, nearly every ... wastewater rather than precious potable water supplies. Across the ... all golf courses receive treated effluent. Reusing the effluent ... golf courses and homeowners alike fertilize their lawns during ... nitrate. A New Mexico State University turfgrass expert has ...
(Date:7/10/2014)... Mass. , June 30, 2014  Aware, Inc. ... biometrics software and services, previously announced on June 26, ... special cash dividend of $1.75 per share, or approximately ... date of July 10, 2014 and a payment date ... by NASDAQ that it had set an ex-dividend date ...
(Date:7/10/2014)... 2014 It is a great honor for ... of the world-renowned Thoracic and Cardiovascular surgeon, Mark E ... Dr. Ginsburg, with over 34 years of experience, is ... Good Samaritan Regional Medical Center. Dr. Ginsburg has been ... and is considered an expert in the implantation of ...
Breaking Biology News(10 mins):'Tailored' water -- the latest in lawn care 2NASDAQ Sets Ex-Dividend Date for Aware, Inc.'s Special Cash Dividend of $1.75 Per Share 2Avery Biomedical Devices, Inc. announces the appointment of Mark E Ginsburg, M.D. to its Board of Directors 2
... , BOSTON -- October 17, 2011-- In a paper published ... headed by Mary R. Loeken, PhD, has identified the enzyme AMP ... the risk of neural tube defects such as spina bifida and ... Even if women with diabetes -- either type 1 or ...
... polyester which occurs naturally in bacteria as Ralstonia ... PHB is biodegradable and is not dependent on fossil ... produce to replace petroleum-based plastics. New research reported in ... describes an alternative method of producing PHB in ...
... have found a way to inject a precise dose of ... without a needle. The technique uses electricity to "shoot" ... a cell in a fraction of a second. L. ... the technique in the online edition of the journal ...
Cached Biology News:Joslin study finds clue to birth defects in babies of mothers with diabetes 2Researchers do precise gene therapy without a needle 2Researchers do precise gene therapy without a needle 3
Tracker Datamatrix RS-1* reads 96 2D Bar-coded tubes within 20 seconds....
Request Info...
... X-Gal ,MOLECULAR BIOLOGY GRADE ,5-Bromo-4-chloro-3-indoxyl-beta-D-galactopyranoside C ... Cl N O 6 ,M.W.= ... ,Solution: Clear (2% in DMF) ,Biological ... and M13 ,Elemental Analysis: Agrees with ...
...
Biology Products: